| AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause |
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause. |
businesswire.com |
2025-05-14 21:00:00 |
Czytaj oryginał (ang.) |
| AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit |
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit. |
businesswire.com |
2025-05-12 19:30:00 |
Czytaj oryginał (ang.) |
| AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting |
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents Positive Preclinical Data on ABCL575 at the SID Annual Meeting 2025. |
businesswire.com |
2025-05-09 23:30:00 |
Czytaj oryginał (ang.) |
| AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript |
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - President and Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Jacqueline Kisa - TD Securities Puneet Souda - Leerink Partners LLC Malcolm Hoffman - BMO Capital Markets Srikripa Devarakonda - Truist Securities Operator Good afternoon, and welcome to AbCellera's First Quarter 2025 Business Update and Conference Call. My name is Jasmine, and I will facilitate the audio portion of today's interactive broadcast. |
seekingalpha.com |
2025-05-09 02:33:06 |
Czytaj oryginał (ang.) |
| AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates |
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.14 per share a year ago. |
zacks.com |
2025-05-08 23:10:57 |
Czytaj oryginał (ang.) |
| AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025 |
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera presents data showing preclinical efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025. |
businesswire.com |
2025-04-29 19:00:00 |
Czytaj oryginał (ang.) |
| AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025 |
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025. |
businesswire.com |
2025-04-03 20:05:00 |
Czytaj oryginał (ang.) |
| AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025 |
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025. |
businesswire.com |
2025-03-25 18:30:00 |
Czytaj oryginał (ang.) |
| AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript |
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Stephen Willey - Stifel Steve Dechert - KeyBanc Jacqueline Kisa - TD Securities Malcolm Hoffman - BMO Capital Markets Operator Good afternoon and welcome to AbCellera's Full Year 2024 Business Update Conference Call. My name is Tamia [ph] and I will facilitate the audio portion of today's interactive broadcast. |
seekingalpha.com |
2025-02-28 01:26:01 |
Czytaj oryginał (ang.) |
| AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates |
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.17 per share a year ago. |
zacks.com |
2025-02-27 21:15:31 |
Czytaj oryginał (ang.) |
| AbCellera Reports Full Year 2024 Business Results |
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Full Year 2024 Business Results. |
businesswire.com |
2025-02-27 18:05:00 |
Czytaj oryginał (ang.) |
| AbCellera to Participate at Upcoming Investor Conferences in March |
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Participate at Upcoming Investor Conferences in March. |
businesswire.com |
2025-02-11 18:05:00 |
Czytaj oryginał (ang.) |
| AbCellera to Report Full Year 2024 Financial Results on February 27, 2025 |
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Full Year 2024 Financial Results on February 27, 2025. |
businesswire.com |
2025-01-21 18:05:00 |
Czytaj oryginał (ang.) |
| AbCellera Biologics: Still A Concept Stock |
Today, we revisit a somewhat unique developmental company called AbCellera Biologics Inc. The company is moving towards focusing more on its wholly owned candidates off its platform rather than partnerships. The company has myriad very early-stage assets in development, and ABCL stock trades near the net cash on its balance sheet. |
seekingalpha.com |
2024-12-23 18:39:37 |
Czytaj oryginał (ang.) |
| AbCellera to Present at Upcoming Investor Conferences in December and January |
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in December and January. |
businesswire.com |
2024-11-21 18:05:00 |
Czytaj oryginał (ang.) |
| AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024 |
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024. |
businesswire.com |
2024-11-07 12:05:00 |
Czytaj oryginał (ang.) |
| AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript |
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Allison Bratzel - Piper Sandler Andrea Tan - Goldman Sachs Srikripa Devarakonda - Truist Securities Evan Seigerman - BMO David Martin - Bloom Burton Brendan Smith - TD Securities Operator Good afternoon, and welcome to AbCellera's Q3 2024 Business Update Conference Call. My name is Tamiya, and I will facilitate the audio portion of today's interactive broadcast. |
seekingalpha.com |
2024-11-04 21:22:20 |
Czytaj oryginał (ang.) |
| AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Misses Revenue Estimates |
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.10 per share a year ago. |
zacks.com |
2024-11-04 20:55:29 |
Czytaj oryginał (ang.) |
| AbCellera to Present at Upcoming Investor Conferences in November 2024 |
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in November 2024. |
businesswire.com |
2024-10-22 20:05:00 |
Czytaj oryginał (ang.) |
| AbCellera: A Platform To Pipeline Transition |
AbCellera is shifting its focus from a platform biotech company to its internal drug pipeline. The company's lead asset, ABCL575, comes with a variety of risks, but in our opinion, has a value of a little over $1B and is derisked based on comparable therapeutics. AbCellera is on track to submit ABCL575 for clinical trials in Q22025, helping the market reset its valuation on the company closer to the value of the lead asset. |
seekingalpha.com |
2024-10-14 16:04:13 |
Czytaj oryginał (ang.) |
| AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024 |
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024. |
businesswire.com |
2024-10-04 13:00:00 |
Czytaj oryginał (ang.) |
| AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 |
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024. |
businesswire.com |
2024-09-26 20:05:00 |
Czytaj oryginał (ang.) |
| AbCellera: A Waiting Game With High Uncertainty |
AbCellera's Q2 2024 revenue declined by 27% year-over-year to $7.3 million. The company's net loss widened to $36.9 million due to increased R&D expenses. AbCellera's cash and marketable securities totaled $697.6 million, with total liquidity exceeding $900 million. |
seekingalpha.com |
2024-08-23 08:43:38 |
Czytaj oryginał (ang.) |
| AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates |
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.11 per share a year ago. |
zacks.com |
2024-08-06 23:15:50 |
Czytaj oryginał (ang.) |
| 5 Penny Stocks With 250% Upside in 1 Year According to Wall Street |
Penny stocks represent an interesting investment opportunity. |
247wallst.com |
2024-07-30 12:49:02 |
Czytaj oryginał (ang.) |
| Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio? |
The Baker brothers acquired millions of shares of AbCellera Biologics and Fate Therapeutics during the first months of 2024. AbCellera Biologics is a drug discovery business with a hand in more than a dozen experimental drugs in clinical-stage development. |
fool.com |
2024-07-21 09:37:00 |
Czytaj oryginał (ang.) |
| AbCellera Biologics (ABCL) Upgraded to Buy: Here's What You Should Know |
AbCellera Biologics (ABCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-07-09 17:01:21 |
Czytaj oryginał (ang.) |
| AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024 |
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024. |
businesswire.com |
2024-06-25 20:05:00 |
Czytaj oryginał (ang.) |
| Down 57%, Is AbCellera Biologics a Buy on the Dip? |
AbCellera Biologics is a biotechnology company built to discover new antibodies for other drugmakers. The stock has fallen more than 90% from its all-time high and by 57% from a peak it set last summer. |
fool.com |
2024-06-13 09:40:00 |
Czytaj oryginał (ang.) |
| AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 |
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024. |
businesswire.com |
2024-05-28 20:05:00 |
Czytaj oryginał (ang.) |
| 3 Stock Gems Hiding in the Nasdaq |
With the technology benchmark Nasdaq index encountering some choppy weather since April, speculators may want to consider undervalued Nasdaq stocks. Granted, it's always risky betting on enterprises that haven't caught other people's attention. |
investorplace.com |
2024-05-13 10:00:00 |
Czytaj oryginał (ang.) |
| AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript |
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & Compliance Officer Carl Hansen - President, Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Andrea Tan - Goldman Sachs Jacqueline Kisa - TD Securities Scott Schoenhaus - KeyBanc Stephen Willey - Stifel Operator Good afternoon and welcome to AbCellera's Q1, 2024 Business Update Conference Call. My name is Harry and I will facilitate the audio portion of today's interactive broadcast. |
seekingalpha.com |
2024-05-08 03:00:08 |
Czytaj oryginał (ang.) |
| AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates |
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.14 per share a year ago. |
zacks.com |
2024-05-07 23:06:08 |
Czytaj oryginał (ang.) |